顾淑燕
特聘研究员
顾淑燕，南京大学政府管理学院准聘助理教授，特聘研究员，博士生导师。浙江大学社会医学与卫生事业管理专业博士，美国杜兰大学公共卫生与热带医学学院全球卫生体系发展与管理系联合培养博士。主要研究领域为健康政策与管理、健康经济、健康行为、卫生技术评估。研究成果主要发表于《Quality of Life Research》、《BMC Medicine》、《Pharmacoeconomics》等中英文学术期刊。主持国家自然科学基金项目及省社会科学基金项目各1项。 · 国家自然科学基金青年项目，基于保护动机理论的社区2型糖尿病患者自我管理行为机制及干预策略研究，2022-2024，主持在研； · 江苏省社会科学基金基地项目，江苏重大突发公共卫生事件多主体协同应急响应机制研究，2021-2022，主持在研； · 国家自然科学基金国际(地区)合作与交流项目，丙型肝炎的诊疗与管理模式构建与优化探索研究，2019-2021，参与； · 浙江省卫生厅一般项目，若干常用基药的药物经济学评价方案设计研究，2014-2016，参与； · 浙江省自然科学基金青年项目，浙江省双向转诊和分级诊疗的社会心理学解决路径，2014-2016，参与； 主要期刊论文 Shuyan Gu, Xiaoyong Wang, Qing Qiao, Weiguo Gao, Jian Wang, Hengjin Dong. Cost-Effectiveness of Exenatide Twice Daily vs Insulin Glargine as Add-on Therapy to Oral Antidiabetic Agents in Patients with Type 2 Diabetes in China. Diabetes Obes Metab. 2017;19:1688-97. Shuyan Gu, Yiming Mu, Suodi Zhai, Yuhang Zeng, Xuemei Zhen, Hengjin Dong. Cost-Effectiveness of Dapagliflozin versus Acarbose as a Monotherapy in Type 2 Diabetes in China. PLoS One. 2016;11:e0165629. Shuyan Gu, Huimei Hu, Hengjin Dong. Systematic Review of the Economic Burden of Pulmonary Arterial Hypertension. PharmacoEconomics. 2016;34:533-50. Shuyan Gu, Yuhang Zeng, Demin Yu, Xiaoqian Hu, Hengjin Dong. Cost-Effectiveness of Saxagliptin versus Acarbose as Second-Line Therapy in Type 2 Diabetes in China. PLoS One. 2016;11:e0167190. Shuyan Gu, Huimei Hu, Hengjin Dong. Systematic Review of Health-Related Quality of Life in Patients with Pulmonary Arterial Hypertension. PharmacoEconomics. 2016;34:751-70. Shuyan Gu, Jing Deng, Lizheng Shi, Yiming Mu, Hengjin Dong. Cost-Effectiveness of Saxagliptin vs Glimepiride as a Second-Line Therapy Added to Metformin in Type 2 Diabetes in China. J Med Econ. 2015;18:808-20. Shuyan Gu, Jihao Shi, Zhiliu Tang, Monika Sawhney, Huimei Hu, Lizheng Shi, Vivian Fonseca, Hengjin Dong. Comparison of Glucose Lowering Effect of Metformin and Acarbose in Type 2 Diabetes Mellitus: a Meta-Analysis. PLoS One. 2015;10:e0126704. Shuyan Gu, Zhiliu Tang, Lizheng Shi, Monika Sawhney, Huimei Hu, Hengjin Dong. Cost-Minimization Analysis of Metformin and Acarbose in Treatment of Type 2 Diabetes. Value Health Reg Issues. 2015;6:84-8.
摘要收录期刊论文 Gu S, Wang X, Shi L, Hu X, Gu Y, Huang M, Dong H. VALUING HEALTH-RELATED QUALITY OF LIFE FOR INPATIENTS WITH DIABETES-RELATED COMPLICATIONS IN CHINA. Value in Health, 2018, 21(S1): S77-8. Gu S, Hu H, Dong H. SYSTEMATIC REVIEW OF HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION. Value in Health, 2016,19(3): A118. Gu S, Dong H. COST-EFFECTIVENESS OF DAPAGLIFLOZIN VERSUS ACARBOSE AS A MONOTHERAPY IN TYPE 2 DIABETES IN CHINA. Value in Health, 2016, 19(7): A898. Gu S, Shao H, Zeng Y, Shi L, Dong H. COST-EFFECTIVENESS OF SAXAGLIPTIN VERSUS ACARBOSE AS SECOND-LINE THERAPY IN TYPE 2 DIABETES IN CHINA. Value in Health, 2016, 19(7): A898. Gu S, Xu X, Shi L, Sawhney M, Hu H, Dong H. COST MINIMIZATION ANALYSIS OF CLINICAL OPTION SCENARIOS FOR METFORMIN AND ACARBOSE IN TREATMENT OF TYPE 2 DIABETES: BASED ON DIRECT AND INDIRECT TREATMENT COMPARISON RESULTS. Value in Health, 2014, 17(7): A745.
主要学术会议 2018年参加国际会议“International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 23rd Annual International Meeting”，作为第一作者发表1篇会议海报 2017年参加国际会议“The International Doctoral Student Conference”，作为第一作者进行口头汇报 2016年参加国际会议“International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 7th Asia-Pacific Conference”，作为第一作者发表2篇会议海报 2016年参加国际会议“2016 Chinese Economists Society Annual Conference”，作为第一作者进行口头汇报 2016年参加国际会议“Health Technology Assessment International (HTAi) 2016 Annual Meeting”，作为第一作者进行2次口头汇报. 2015年参加国内会议“中华预防医学会社会医学分会第十一次全国社会医学学术年会”，作为第一作者发表1篇会议论文. 2015年参加国际会议“Symposium on Social Determinants of Health”，作为嘉宾在会上发言并参与讨论. 2015年参加国际会议“12th Health Technology Assessment International (HTAi) Annual Meeting”，作为第一作者发表1篇会议海报. 2014年参加国际会议“International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 6th Asia-Pacific Conference”，作为第一作者发表1篇会议海报. 2013年参加国内会议“中华预防医学会第四届学术年会”，作为第一作者发表1篇会议论文.
|
||||||
